| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1042309842 |
| P356 | DOI | 10.1038/NRC1365 |
| P698 | PubMed publication ID | 15122208 |
| P2093 | author name string | Stanley R Riddell | |
| Marie Bleakley | |||
| P2860 | cites work | In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens | Q77859052 |
| Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease | Q77966217 | ||
| Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens | Q24673417 | ||
| The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing | Q24675797 | ||
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 | ||
| Reliable prediction of T-cell epitopes using neural networks with novel sequence representations | Q27485882 | ||
| The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein | Q28187004 | ||
| WT1 proteins: functions in growth and differentiation | Q28191433 | ||
| Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants | Q29619458 | ||
| A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. | Q30274634 | ||
| The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. | Q30307859 | ||
| Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein | Q30464516 | ||
| The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition | Q30470188 | ||
| The genetic program of hematopoietic stem cells | Q30874287 | ||
| A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease | Q32061758 | ||
| Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma | Q33348936 | ||
| Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes | Q33811112 | ||
| The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. | Q33890464 | ||
| The HLA system. First of two parts | Q34023681 | ||
| Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy | Q34089112 | ||
| Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression | Q34118755 | ||
| The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. | Q34121730 | ||
| Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation | Q34186689 | ||
| Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells | Q34415738 | ||
| Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus | Q34777218 | ||
| Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia | Q34808353 | ||
| Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant | Q34931009 | ||
| The current status of hematopoietic cell transplantation | Q34987985 | ||
| Alloreactive killer cells: hindrance and help for haematopoietic transplants | Q35058540 | ||
| Adoptive-cell-transfer therapy for the treatment of patients with cancer | Q35210008 | ||
| Minor histocompatibility antigens in human stem cell transplantation | Q35214671 | ||
| CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells | Q35558987 | ||
| Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes | Q36230215 | ||
| A human minor histocompatibility antigen resulting from differential expression due to a gene deletion | Q36370375 | ||
| Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts | Q39244446 | ||
| Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. | Q39741064 | ||
| Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease | Q40627364 | ||
| Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes | Q40700703 | ||
| Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus | Q40705556 | ||
| Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes | Q40750584 | ||
| Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer | Q40777946 | ||
| Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes | Q40811313 | ||
| The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. | Q41061835 | ||
| Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality | Q43819629 | ||
| Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia | Q44189831 | ||
| HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies | Q44468881 | ||
| Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia | Q44611047 | ||
| Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes | Q45771097 | ||
| A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency | Q45857796 | ||
| T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients | Q45876112 | ||
| HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia | Q45882160 | ||
| Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. | Q47385454 | ||
| Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. | Q47438492 | ||
| Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia | Q47626366 | ||
| Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants | Q47631013 | ||
| Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies | Q47752014 | ||
| Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients | Q47853618 | ||
| In vivo migration and function of transferred HIV-1-specific cytotoxic T cells | Q47995100 | ||
| Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. | Q52006998 | ||
| Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. | Q52961647 | ||
| Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. | Q53659254 | ||
| Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. | Q54790078 | ||
| Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. | Q55510169 | ||
| Identification of a graft versus host disease-associated human minor histocompatibility antigen | Q56929110 | ||
| The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells | Q57556495 | ||
| Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation | Q64038880 | ||
| Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones | Q67518698 | ||
| Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation | Q70812614 | ||
| Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor | Q72059554 | ||
| Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells | Q72585119 | ||
| Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation | Q73117300 | ||
| Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region | Q73686876 | ||
| Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation | Q73874939 | ||
| Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease | Q74122363 | ||
| Acute graft-versus-host disease does not require alloantigen expression on host epithelium | Q74221421 | ||
| Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia | Q74268543 | ||
| Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion | Q74284634 | ||
| Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients | Q74456064 | ||
| Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA | Q74794179 | ||
| Absence of statistically significant correlation between disparity for the minor histocompatibility antigen-HA-1 and outcome after allogeneic hematopoietic cell transplantation | Q77228594 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 371-380 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | Molecules and mechanisms of the graft-versus-leukaemia effect | |
| P478 | volume | 4 |
| Q52959192 | A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4+ or CD8+ T Cells Using Immunodeficient NOG Mice. |
| Q54672071 | A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. |
| Q40404804 | A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells |
| Q81357571 | A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses |
| Q36057568 | A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. |
| Q24536117 | A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia |
| Q33492227 | A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. |
| Q87969904 | A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells |
| Q33955292 | A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen ZAPHIR. |
| Q39991512 | Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: application for allogeneic transplantation |
| Q37930715 | Acute graft-versus-host disease following hematopoietic stem-cell transplantation |
| Q37810116 | Adoptive T-cell therapy for B-cell malignancies |
| Q27006934 | Adoptive T-cell therapy for Leukemia |
| Q37016470 | Adoptive immunotherapy against allogeneic kidney grafts in dogs with stable hematopoietic trichimerism |
| Q38199350 | Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition |
| Q36183567 | Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates |
| Q33967995 | Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. |
| Q90999899 | Allogeneic dendritic cells induce potent antitumor immunity by activating KLRG1+CD8 T cells |
| Q36310235 | Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders |
| Q34564542 | An antigen produced by splicing of noncontiguous peptides in the reverse order. |
| Q35849500 | Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation |
| Q46578433 | Antileukemic immunity associated with antineutrophil antibody production after allogeneic hematopoietic SCT for myeloid/NK-cell precursor acute leukemia |
| Q38007178 | Apoptotic cells in allogeneic hematopoietic stem cell transplantations: "turning trash into gold". |
| Q36556944 | Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation |
| Q36662079 | Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation |
| Q34146648 | Both positive and negative effects on immune responses by expression of a second class II MHC molecule. |
| Q33359498 | C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients |
| Q36508991 | CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. |
| Q56901286 | CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease |
| Q95272135 | Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions |
| Q37398584 | Cancer stem cells: relevance to SCT |
| Q24814450 | Cancer vaccines: the next generation of tools to monitor the anticancer immune response |
| Q36015241 | Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD. |
| Q37132892 | Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation |
| Q44535281 | Circulating IL-17 levels during the peri-transplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation |
| Q37868974 | Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia |
| Q64084614 | Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model |
| Q36499204 | Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7 |
| Q38792076 | Conditional control of suicide gene expression in tumor cells with theophylline-responsive ribozyme |
| Q35876347 | Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia. |
| Q40128840 | Deep-sequencing of the T-cell receptor repertoire in patients with haplo-cord and matched-donor transplants. |
| Q48523192 | Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse |
| Q37447307 | Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia |
| Q33709766 | Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes |
| Q37832506 | Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation |
| Q30558271 | Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose |
| Q39324107 | Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. |
| Q37291529 | Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. |
| Q36707403 | Eicosanoid regulation of pulmonary innate immunity post-hematopoietic stem cell transplantation |
| Q92573835 | Endowing human CD8 T cells with a veto-like recognition capacity via the electroporation of MHC-I/CD3ζ mRNA |
| Q45859255 | Evaluation of interleukin 12 and CD56+ lymphocyte cells in pediatric hematopoietic stem cell transplantation for early diagnosis of acute graft versus host disease |
| Q60635004 | Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation |
| Q42645889 | Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients |
| Q34443622 | Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning |
| Q36863475 | Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. |
| Q34163218 | Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia |
| Q54537324 | Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. |
| Q37216330 | Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy |
| Q82350569 | Expressions of tissue factor and tissue factor pathway inhibitor in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation |
| Q88797008 | Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts |
| Q35990075 | Finding a place for tumor-specific T cells in targeted cancer therapy |
| Q34093814 | Frequencies of 10 autosomal minor histocompatibility antigens in Korean population and estimated disparities in unrelated hematopoietic stem cell transplantation. |
| Q37973859 | GVHD prevention: an ounce is better than a pound |
| Q28069956 | Genetic barriers in transplantation medicine |
| Q36909362 | Genetic modification of T cells for immunotherapy |
| Q35726310 | Genome-wide single-nucleotide polymorphism analysis revealed SUFU suppression of acute graft-versus-host disease through downregulation of HLA-DR expression in recipient dendritic cells |
| Q83468020 | Graft-versus-host disease |
| Q36793622 | Graft-versus-host disease |
| Q26824540 | Graft-versus-host disease biomarkers: omics and personalized medicine |
| Q33290423 | Graft-versus-host disease: a surge of developments |
| Q84570342 | Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL |
| Q35016985 | HDAC inhibition and graft versus host disease |
| Q37635354 | HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect |
| Q39624857 | HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands |
| Q36791906 | HapMap SNP Scanner: an online program to mine SNPs responsible for cell phenotype |
| Q40731565 | HapMap scanning of novel human minor histocompatibility antigens |
| Q36850864 | Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation |
| Q37202298 | Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease |
| Q39362145 | Humanized mouse models: Application to human diseases |
| Q82287260 | IL-21-treated naive CD45RA+ CD8+ T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype |
| Q33677067 | Identification of MHC II-Restricted Minor Histocompatibility Antigens After HLA-Identical Stem-Cell Transplantation |
| Q51343627 | Identification of a novel UTY-encoded minor histocompatibility antigen. |
| Q48273861 | Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword |
| Q36802900 | Immunogenicity of pluripotent stem cells and their derivatives |
| Q33731552 | Immunotherapy in acute leukemia |
| Q37718264 | Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides |
| Q36490755 | Induction of tumor immunity following allogeneic stem cell transplantation |
| Q34683729 | Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation |
| Q43737293 | KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts |
| Q33931811 | Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells |
| Q36220062 | Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease |
| Q33634455 | Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients |
| Q36751574 | Mechanisms of minor histocompatibility antigen immunogenicity: the role of infinitesimal versus structurally profound polymorphisms |
| Q35585983 | Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution |
| Q37874011 | Mouse models of graft-versus-host disease: advances and limitations |
| Q35605318 | NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma |
| Q37641063 | New perspectives on the biology of acute GVHD. |
| Q35211577 | Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome |
| Q38664735 | Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? |
| Q37822742 | Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma. |
| Q26770391 | Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic) |
| Q36026057 | Novel role for surfactant protein A in gastrointestinal graft-versus-host disease |
| Q37163474 | Ocular manifestations of graft-versus-host disease |
| Q36556498 | Optimization of allogeneic transplant conditioning: not the time for dogma |
| Q52881816 | Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index. |
| Q36444449 | Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011 |
| Q35921900 | PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. |
| Q34077479 | Pathogenesis and management of graft-versus-host disease. |
| Q36156559 | Pathophysiology of acute graft-versus-host disease: recent advances |
| Q50708752 | Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice. |
| Q36777599 | Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I |
| Q46217108 | Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients |
| Q83071687 | Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse |
| Q56897193 | Polymorphism of costimulatory molecules (CTLA4, ICOS, PD.1 and CD28) and allogeneic hematopoietic stem cell transplantation in Iranian patients |
| Q34063337 | Polymorphisms in the base excision repair pathway and graft-versus-host disease |
| Q40337388 | Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy |
| Q33999335 | Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy. |
| Q37216610 | Prowling wolves in sheep's clothing: the search for tumor stem cells |
| Q36045031 | Rapid Recovery of CD3+CD8+ T Cells on Day 90 Predicts Superior Survival after Unmanipulated Haploidentical Blood and Marrow Transplantation |
| Q39089535 | Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice. |
| Q34065058 | Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited |
| Q37966037 | Role of microRNAs in immunity and organ transplantation. |
| Q27653882 | Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition. |
| Q42699915 | Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor |
| Q33627040 | Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit |
| Q60938512 | Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease |
| Q35588845 | Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation |
| Q89108831 | Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation |
| Q27676136 | Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction |
| Q33917224 | Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia |
| Q98664989 | T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect |
| Q24634774 | T cell receptor gene therapy for cancer |
| Q81357568 | T cells targeted against a single minor histocompatibility antigen can cure solid tumors |
| Q90176790 | T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies |
| Q35041966 | T-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and function |
| Q55090588 | Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy. |
| Q39026731 | Targeting high-grade B cell lymphoma with CD19-specific T cells |
| Q36994811 | Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses |
| Q84963435 | The Origin and Role of MHC Class I-Associated Self-Peptides |
| Q24685666 | The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. |
| Q39544554 | The genotype of RAET1L (ULBP6), a ligand for human NKG2D (KLRK1), markedly influences the clinical outcome of allogeneic stem cell transplantation |
| Q38243215 | The graft-versus-neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms |
| Q24296246 | The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -A*3303 |
| Q39182194 | The human leukocyte antigen-presented ligandome of B lymphocytes |
| Q91430045 | The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells |
| Q37543431 | The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease |
| Q33849560 | Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens |
| Q41592770 | Time to Akt: Superior tumor-reactive T cells for adoptive immunotherapy |
| Q36605959 | Titrating graft-versus-host disease: is it worth a try? |
| Q34979770 | Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation |
| Q36793112 | Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias |
| Q33398031 | Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice |
| Q36125603 | Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the A |
| Q37910960 | Use of NK cell activity in cure by transplant |
| Q36328410 | Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? |
| Q64983510 | Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice. |
| Q36661849 | miR-146a and miR-155 Expression Levels in Acute Graft-Versus-Host Disease Incidence |
| Q35546869 | siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice |
Search more.